VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Ana Oaknin ,L Gladieff,U.F.F De Giorgi,L Fariñas Madrid,Linda R Duska ,Véronique D’hondt ,Antoine Angelergues ,Kristina Lindemann ,Satoshi Yamaguchi ,A Ortiz ,Jerónimo Martínez-García ,Guillermo Villacampa ,Munetaka Takekuma ,Alexandra Léary ,Shin Nishio ,Nicoletta Colombo ,M.j Rubio Pérez ,Linn Woelber ,Domenica Lorusso ,Leslie M Randall

doi:10.1016/j.annonc.2023.10.694

Abstract

VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Full Text